New Building Blocks for April 2022_ChemScene -코아사이언스

안녕하세요!

Building Blocks & Bioactive Molecules 전문제조사 ChemScene 수입/공급 업체 코아사이언스 입니다.

 

자세한 상품 정보 및 관련 문의는 전화 02-858-0328 또는 info@coresciences.co.kr로 문의주시기 바랍니다.

감사합니다!

KRAS, the most frequently mutated oncogene, plays a predominant role in driving initiation and progression of cancers. Decades of effort to target KRAS using small molecules has been unsuccessful, causing KRAS to be considered an “undruggable” cancer target[1]. However, this view began to change recently, as drug discovery techniques have developed several KRAS allosteric inhibitors. in May 2021, Amgen's KRAS G12C inhibitor, commonly known as Sotorasib, was approved by the US FDA and was the first targeted drug for the treatment of cancer with KRAS gene mutation in the world. At present, a number of small molecule drugs targeting KRAS G12C are in clinical stages and the fastest progress is adagrasib (MATX849) of Mirati therapeutics, which is expected to become the second KRAS G12C targeted drug in the world. And on December 10, 2021, Journal of Medicinal Chemistry reported the discovery and characterization of the first Noncovalent, Potent, and Selective KRAS G12D Inhibitor MARTX1133[2-9].

[1] Journal of Medicinal Chemistry (2020), 63, 23, 14404-14424.
[2] WO2018217651A1.
[3] Journal of Medicinal Chemistry (2022), 65, 4, 3123-3133.
[4] Nature (2019), 575, 217-223.
[5] WO2020102730A1.
[6] Journal of Medicinal Chemistry (2020), 63, 1, 52-65.
[7] Journal of Medicinal Chemistry (2020), 63, 13, 6679-6693.
[8] ACS Medicinal Chemistry Letters (2022), 13, 1, 11-12..
[9] WO2021124222A1.

 

 

코아사이언스 coresciences Chemscene Korea 한국 대리점 Korea distributor pharmaceutical ingredients natural compounds standards